1983
Panic-Induced Elevation of Plasma MHPG Levels in Phobic-Anxious Patients: Effects of Clonidine and Imipramine
Ko G, Elsworth J, Roth R, Rifkin B, Leigh H, Redmond D. Panic-Induced Elevation of Plasma MHPG Levels in Phobic-Anxious Patients: Effects of Clonidine and Imipramine. JAMA Psychiatry 1983, 40: 425-430. PMID: 6838322, DOI: 10.1001/archpsyc.1983.01790040079011.Peer-Reviewed Original ResearchConceptsPlasma MHPG levelsMHPG levelsEffects of clonidineSignificant symptom reductionPlasma MHPG concentrationSelf-rated anxietyPlacebo treatmentCrossover trialMHPG concentrationsPlasma levelsNoradrenergic activityDrug treatmentDrug trialsSymptom reductionDiminished suppressionPanic attacksPanic symptomsImipramine hydrochlorideClonidinePatientsPhobic stimuliImipramineTrialsAnxietyTreatment
1982
The contribution of amphetamine metabolites of (−)-deprenyl to its antiparkinsonian properties
Elsworth J, Sandler M, Lees A, Ward C, Stern G. The contribution of amphetamine metabolites of (−)-deprenyl to its antiparkinsonian properties. Journal Of Neural Transmission 1982, 54: 105-110. PMID: 6809891, DOI: 10.1007/bf01249283.Peer-Reviewed Original Research
1977
DEPRENYL IN PARKINSON'S DISEASE
Lees A, Kohout L, Shaw K, Stern G, Elsworth J, Sandler M, Youdim M. DEPRENYL IN PARKINSON'S DISEASE. The Lancet 1977, 310: 791-795. PMID: 71602, DOI: 10.1016/s0140-6736(77)90725-5.Peer-Reviewed Original ResearchConceptsParkinson's diseaseDouble-blind crossover trialDoses of levodopaEarly morning akinesiaPeripheral decarboxylase inhibitorLevodopa-induced dyskinesiaTotal daily dosesMajority of patientsIdiopathic Parkinson's diseaseDose akinesiaUntreated patientsCrossover trialDosage reductionDaily dosesDecarboxylase inhibitorTherapeutic effectCheese effectLarge dosesPatientsLevodopaAlternate daysAkinesiaDeprenylDiseaseB inhibitor